Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma

BACKGROUND: Immune checkpoint inhibitors (ICI) induce a range of immune-related adverse events (irAEs) with various degrees of severity. While clinical experience with ICI retreatment following clinically significant irAEs is growing, the safety and efficacy are not yet well characterized. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Abou Alaiwi, Sarah, Xie, Wanling, Nassar, Amin H, Dudani, Shaan, Martini, Dylan, Bakouny, Ziad, Steinharter, John A, Nuzzo, Pier Vitale, Flippot, Ronan, Martinez-Chanza, Nieves, Wei, Xiao, McGregor, Bradley A, Kaymakcalan, Marina D, Heng, Daniel Y C, Bilen, Mehmet A, Choueiri, Toni K, Harshman, Lauren C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057439/
https://www.ncbi.nlm.nih.gov/pubmed/32066646
http://dx.doi.org/10.1136/jitc-2019-000144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057439/
https://www.ncbi.nlm.nih.gov/pubmed/32066646
http://dx.doi.org/10.1136/jitc-2019-000144

Ejemplares similares